Search: onr:"swepub:oai:DiVA.org:uu-475551" >
Poor outcome after ...
Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
-
- Mollazadegan, Kazhan (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Skogseid, Britt (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Botling, Johan (author)
- Uppsala universitet,Klinisk och experimentell patologi
-
show more...
-
- Åkerström, Tobias (author)
- Uppsala universitet,Endokrinkirurgi
-
- Eriksson, Barbro (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Welin, Staffan (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Sundin, Anders, 1954- (author)
- Uppsala universitet,Radiologi
-
- Crona, Joakim (author)
- Uppsala universitet,Endokrin tumörbiologi
-
show less...
-
(creator_code:org_t)
- Bioscientifica, 2022
- 2022
- English.
-
In: Endocrine Connections. - : Bioscientifica. - 2049-3614. ; 11:3
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. This was a single-center retrospective cohort study aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 22 patients were included and received a median of 2 (range, 1–4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25–17.5). For the 15 patients who received platinum–etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75–10) and median progression-free survival (PFS) was 4 months (IQR: 2.5–5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR: 5–16.75) and median PFS was 5.5 months (IQR: 2.75–8.25). We observed one partial response on 177Lu DOTA-TATE therapy. In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- pancreatic neuroendocrine tumor
- highgrade
- systemic therapy
- treatment outcomes
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database